颈椎间盘突出症、术后综合征或椎间盘源性疼痛的颈椎间层硬膜外注射治疗:来自随机试验的成本效用分析。
Cervical Interlaminar Epidural Injections in the Treatment of Cervical Disc Herniation, Post Surgery Syndrome, or Discogenic Pain: Cost Utility Analysis from Randomized Trials.
机构信息
Pain Management Centers of America, Paducah, KY and Evansville, IN; LSU Health Science Center, New Orleans, LA.
Pain Management Center of Paducah.
出版信息
Pain Physician. 2019 Sep;22(5):421-431.
BACKGROUND
Neck pain is one of the major conditions attributing to overall disability in the United States. There have been multiple publications assessing clinical and cost effectiveness of multiple modalities of interventions in managing chronic neck pain. Even then, the literature has been considered sparse in relation to cervical interlaminar epidural injections in managing chronic neck pain. In contrast, cost utility studies of lumbar interlaminar injections, caudal epidural injections, cervical and lumbar facet joint nerve blocks, percutaneous adhesiolysis demonstrated costs of less than $3,500 for quality-adjusted life year (QALY).
OBJECTIVES
To assess the cost utility of cervical interlaminar epidural injections in managing chronic neck and/or upper extremity pain secondary to cervical disc herniation, post-surgery syndrome in neck, and axial or discogenic neck pain.
STUDY DESIGN
Analysis based on 3 previously published randomized trials of the effectiveness of cervical interlaminar epidural injections assessing their role in disc herniation, cervical post-surgery syndrome, and axial or discogenic pain.
SETTING
A contemporary, private, specialty referral interventional pain management center in the United States.
METHODS
Cost utility of cervical interlaminar epidural injections with or without steroids in managing cervical disc herniation, cervical post-surgery syndrome, and cervical discogenic or axial neck back pain was conducted with data derived from 3 randomized controlled trials (RCTs) that included a 2-year follow-up, with inclusion of 356 patients. The primary outcome was significant improvement defined as at least 50% in pain reduction and disability status. Direct payment data from all carriers from 2018 was utilized for the assessment of procedural costs. Overall costs, including drug costs, were determined by multiplication of direct procedural payment data by a factor of 1.67 to accommodate for indirect payments respectively for disc herniation, discogenic pain, and cervical post-surgery syndrome.
RESULTS
The results of the 3 RCTs showed direct cost utility for one year of QALY of $2,412.31 for axial or discogenic pain without disc herniation, $2,081.07 for disc herniation, and $2,309.20 for post surgery syndrome, with an average cost per one year QALY of $2,267.57, with total estimated overall costs with addition of indirect costs of $3,475.38, $4,028.55, $3,856.36, and $3,785.89 respectively.
LIMITATIONS
The limitation of this cost utility analysis includes that it is a single center evaluation. Indirect costs were extrapolated.
CONCLUSION
This cost utility analysis of cervical interlaminar epidural injections in patients nonresponsive to conservative management in the treatment of disc herniation, post surgery syndrome and axial or discogenic neck pain shows $2,267.57 for direct costs with a total cost of $3,785.89 per QALY.
KEY WORDS
Cervical interlaminar epidural injections, chronic neck pain, cervical disc herniation, cervical discogenic pain, post surgery syndrome, cost utility analysis, cost effectiveness analysis, quality-adjusted life years.
背景
颈部疼痛是导致美国整体残疾的主要原因之一。已经有多项出版物评估了多种干预措施在治疗慢性颈部疼痛方面的临床和成本效益。即便如此,与管理慢性颈部疼痛的颈椎间硬膜外注射相关的文献仍然被认为是稀少的。相比之下,腰椎间硬膜外注射、骶管硬膜外注射、颈椎和腰椎关节突关节神经阻滞、经皮松解粘连术的成本效用研究显示,每质量调整生命年(QALY)的成本低于 3500 美元。
目的
评估颈椎间硬膜外注射治疗颈椎间盘突出症、颈部手术后综合征和轴向或椎间盘源性颈部疼痛引起的慢性颈痛和/或上肢疼痛的成本效用。
研究设计
基于 3 项先前发表的关于颈椎间硬膜外注射有效性的随机试验进行分析,评估其在椎间盘突出症、颈椎手术后综合征和轴向或椎间盘源性疼痛中的作用。
设置
美国一家现代的、私人的、专业的转诊介入性疼痛管理中心。
方法
对伴有或不伴有类固醇的颈椎间硬膜外注射治疗颈椎间盘突出症、颈椎手术后综合征和颈椎椎间盘源性或轴向颈部背痛的成本效用进行了评估,这些数据来自 3 项包括 2 年随访的随机对照试验(RCT),共纳入 356 例患者。主要结果是定义为疼痛减轻至少 50%和残疾状态改善的显著改善。2018 年所有保险公司的直接支付数据用于评估程序成本。包括药物成本在内的总费用通过将直接程序支付数据乘以 1.67 来确定,以分别适应椎间盘突出症、椎间盘源性疼痛和颈椎手术后综合征的间接支付。
结果
3 项 RCT 的结果显示,无椎间盘突出症的轴向或椎间盘源性疼痛的一年 QALY 的直接成本效用为 2412.31 美元,椎间盘突出症为 2081.07 美元,手术后综合征为 2309.20 美元,平均一年 QALY 的成本为 2267.57 美元,加上间接成本的总估计费用为 3475.38 美元、4028.55 美元、3856.36 美元和 3785.89 美元。
局限性
本成本效用分析的局限性在于它是一项单中心评估。间接成本是推断出来的。
结论
这项对颈椎间硬膜外注射治疗对保守治疗无反应的椎间盘突出症、手术后综合征和轴向或椎间盘源性颈部疼痛患者的成本效用分析显示,直接成本为 2267.57 美元,每 QALY 的总成本为 3785.89 美元。
关键词
颈椎间硬膜外注射、慢性颈部疼痛、颈椎间盘突出症、颈椎椎间盘源性疼痛、手术后综合征、成本效用分析、成本效果分析、质量调整生命年。